Illumina partners with Singapore for whole genome sequencing research initiative
Biotechnology firm Illumina secured a selection to support the SG INSIGHT clinical study expanding whole genome sequencing coverage to nearly ten per cent of Singapore residents
SINGAPORE – Illumina, Inc. (Nasdaq: ILMN) has been chosen to supply whole-genome sequencing services for the SG-INSIGHT study, a cohort of approximately 450,000 Singapore residents. This Phase III study, part of the National Precision Medicine (NPM) programme, aims to generate evidence from genomic and health data to inform preventive healthcare approaches.
The study represents a shift from studying healthy volunteers to those with various medical conditions, enabling better understanding of disease and treatment responses. Jacob Thaysen, CEO of Illumina, emphasized that this collaboration will advance understanding of disease, support responsible genetic screening, and contribute to personalized healthcare.
Professor Patrick Tan, Executive Director of PRECISE, highlighted the importance of extending the programme to patients across the public healthcare system to deepen understanding of genetic, lifestyle, and environmental factors. Illumina will conduct sequencing in Singapore through its local genomics facility, which will ensure compliance with Singapore's Healthcare Services Act 2020.
The company's selection for the SG-INSIGHT Study was made through an international competitive tender, building upon a multi-year engagement supporting the Phase II study. Illumina's long-standing presence in Singapore, established in 2008, serves as the company's Asia Pacific regional headquarters and one of its largest hubs outside the United States, with over 1,700 employees across three locations.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
